- Boston Scientific ( NYSE: BSX ) acquired privately-held Obsidio, a developer of Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature.
- Terms of the transaction were not disclosed.
- Embolization is a procedure to stop or reduce blood flow to an abnormal area of a tissue or tumor to stop hemorrhaging, and reduce the size of tumors.
- The GEM technology is a semi-solid, proprietary material packaged in a ready-to-use form, thus reducing the preparation time for many embolization procedures, BSX said in an Aug. 15 press release.
- BSX noted that the acquisition strengthens its interventional oncology and embolization portfolio.
- The transaction is expected to be immaterial to Boston Scientific's GAAP and adjusted EPS in 2022, the company added.
For further details see:
Boston Scientific acquires Obsidio to bolster embolization portfolio